{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:24:18Z","timestamp":1767626658297,"version":"build-2065373602"},"reference-count":22,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:00:00Z","timestamp":1632009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared \u201con label\u201d and \u201coff label\u201d use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated \u201coff-label\u201d.<\/jats:p>","DOI":"10.3390\/antibiotics10091129","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T07:52:14Z","timestamp":1632124334000},"page":"1129","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center"],"prefix":"10.3390","volume":"10","author":[{"given":"Lucia","family":"Brescini","sequence":"first","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Della Martera","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Morroni","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mazzanti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Di Pietrantonio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Mantini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Candelaresi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pallotta","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Iencinella","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"},{"name":"Infectious Diseases, Ospedali Riuniti Umberto I, ViaConca 71, 60126 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sefora","family":"Castelletti","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Ospedali Riuniti Umberto I, ViaConca 71, 60126 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Cocci","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria G.","family":"Polo","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Veccia","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Cirioni","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tavio","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Ospedali Riuniti Umberto I, ViaConca 71, 60126 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giacometti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Via Conca 71, 60126 Torrette, AN, Italy"},{"name":"Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Via Tronto 10\/a, 60020 Torrette, AN, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/TCRM.S271445","article-title":"Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization","volume":"17","author":"Simonetti","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijantimicag.2017.05.006","article-title":"Recently Approved Antibacterials for Methicillin-Resistant Staphylococcus Aureus (MRSA) and Other Gram-Positive Pathogens: The Shock of the New","volume":"50","author":"David","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e02062-19","DOI":"10.1128\/AAC.02062-19","article-title":"New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection","volume":"64","author":"Simonetti","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/QCO.0000000000000430","article-title":"The Role of Dalbavancin in Skin and Soft Tissue Infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: A Novel Antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Dalbavancin Skin and Soft-Tissue Infection Study Group Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the Treatment of Different Gram-Positive Infections: A Real-Life Experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-World Experience with Dalbavancin Therapy in Gram-Positive Skin and Soft Tissue Infection, Bone and Joint Infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter Clinical Experience of Real Life Dalbavancin Use in Gram-Positive Infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/phar.2389","article-title":"Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review","volume":"40","author":"Krsak","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e02280-18","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"French National Cohort of First Use of Dalbavancin: A High Proportion of off-Label Use","volume":"54","author":"Dinh","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) and Other Infections in a Real-Life Setting: Data from an Italian Observational Multicentric Study (DALBITA Study)","volume":"18","author":"Bai","year":"2020","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0213-005X(17)30032-0","article-title":"Analysis of dalbavancin in animal models","volume":"35","author":"Murillo","year":"2017","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkv357","article-title":"Efficacy of Dalbavancin in the Treatment of MRSA Rat Sternal Osteomyelitis with Mediastinitis","volume":"71","author":"Barnea","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"doi-asserted-by":"crossref","unstructured":"Buz\u00f3n-Mart\u00edn, L., Zollner-Schwetz, I., Tobudic, S., Cercenado, E., and Lora-Tamayo, J. (2021). Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. Antibiotics, 10.","key":"ref_22","DOI":"10.3390\/antibiotics10060656"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/9\/1129\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:02:19Z","timestamp":1760166139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/9\/1129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,19]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["antibiotics10091129"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10091129","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2021,9,19]]}}}